Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

9.290 +0.190 (+2.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,268,244
Open 8.990
Bid (Size) 9.000 (1,000)
Ask (Size) 9.500 (700)
Prev. Close 9.100
Today's Range 8.950 - 9.320
52wk Range 6.000 - 11.22
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
From BioCryst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
From BioCryst Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+23.9%
+23.9%
1 Month
+4.1%
+4.1%
3 Month
-2.4%
-2.4%
6 Month
+29.6%
+29.6%
1 Year
+8.1%
+8.1%

More News

Read More
News headline image
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances ↗
Via MarketBeat
News headline image
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings ↗
Via Benzinga
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Q1 2026 Results: Revenue Beat, EPS Miss ↗
Via Chartmill
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Shatters Q4 2025 Estimates with Stellar Earnings Beat ↗
Via Chartmill
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
BioCryst (BCRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play ↗
Via Stocktwits
BioCryst To Acquire Astria Therapeutics In $700M Deal ↗
Via Stocktwits
News headline image
BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
Via Benzinga
News headline image
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗
Via Chartmill
Topics Earnings
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' ↗
Via Benzinga
News headline image
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Via MarketMinute
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
Via Benzinga
News headline image
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level ↗
Via Stocktwits
Topics Artificial Intelligence Earnings

Frequently Asked Questions

Is BioCryst Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, BioCryst Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does BioCryst Pharmaceuticals, Inc. - Common Stock trade on?
BioCryst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock is BCRX on the Nasdaq Stock Market
What is the current price of BioCryst Pharmaceuticals, Inc. - Common Stock?
The current price of BioCryst Pharmaceuticals, Inc. - Common Stock is 9.290
When was BioCryst Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of BioCryst Pharmaceuticals, Inc. - Common Stock was at 07/17/26 04:00 PM ET
What is the market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock?
The market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock is 1.72B
How many shares of BioCryst Pharmaceuticals, Inc. - Common Stock are outstanding?
BioCryst Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.